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Abstract 14 
The present work describes the development of a robust and sensitive targeted analysis 15 
platform for the simultaneous quantification in blood plasma of lipid oxygenated 16 
mediators and fatty acids using Solid-phase Extraction (SPE) and high performance 17 
liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS). The 18 
concurrent analysis of these lipid mediators is challenging because of their instability, 19 
differences in solubility and the often occurrence of isobaric forms with similar 20 
fragmentation patterns. Results demonstrated that the reduction of SPE temperature to 21 
4ºC is a critical parameter for preserving the hydroperoxy derivatives. Polymeric HLB 22 
cartridges increased 40-50% ARA, EPA and DHA sensitivity compared to C18 sorbent, 23 
and also provided higher global performance for most hydroxides and other oxidation 24 
products. The proposed method yields for two tested mass analyzers high sensitivity, 25 
good linearity and reproducibility, with detection limits ranging 0.002-7 ng/mL and 26 
global recoveries as high as 85-112%. However, it should be noted the additional 27 
advantage of the linear ion trap (LIT) mass analyzer acquiring in full scan product ion 28 
mode, compared to the triple quadrupole (QqQ) acquiring in Multiple Reaction 29 
Monitoring (MRM): the full scan product ion mode provides the full fragmentation 30 
spectra of compounds that allowed to discriminate coeluting isomers and false positive 31 
identifications without additional chromatography development. The proposed 32 
lipidomic procedure demonstrates to be confident, simple and sensitive to profile in 33 
plasma a wide range of lipid eicosanoid and docosanoid mediators, including 34 
innovatively the analysis of hydroperoxy congeners and non-oxidized PUFA precursors. 35 
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1. Introduction 41 
Polyunsaturated fatty acids (PUFAs) exhibit a range of biological effects, many of 42 
which are mediated by the formation of lipid derivatives. Such metabolites are produced 43 
in vivo through the action of cyclooxygenases (COXs), lipooxygenases (LOXs), 44 
cytochrome P450 monooxygenases (CYP450) and/or free radical oxidation mechanisms 45 
[1]. PUFAs with twenty carbons like arachidonic acid (ARA) and eicosapentaenoic acid 46 
(EPA) are precursors of many eicosanoids like prostanoids (prostaglandins and 47 
tromboxanes) and leukotrienes, a family of compounds involved in inflammatory 48 
processes [2]. From ARA, series-2 prostanoids like PGE2, PGD2 or TXB2 and series-4 49 
leukotrienes like LTB4 and also hydroxyeicosatetraenoic acids (HETEs) are generated 50 
by COXs and LOXs activity [3]; whilst CYP450 and autoxidation reactions result in 51 
various hydroxy-, hydroperoxy-, epoxy-fatty acids and F2-isoprostanes [4]. In a similar 52 
 2
manner, from EPA derive many lipid compounds including series-3 prostanoids (e.g., 1 
PGE3, PGD3 and TXB3), series-5 leukotrienes (e.g., LTB5), hydroxy- and hydroperoxy- 2 
eicosapentaenoic acids (HEPEs and HpEPEs) [5][6]. From EPA also derive F3-3 
isoprostanes (a group of analgesic compounds) [2][7], and series-E resolvins (e.g., RvE1 4 
and RvE2) which are a novel discovered family of trihydroxy congeners that result from 5 
COX-2 activity and act as anti-inflammatory mediators [3][8]. 6 
 7 
Enzymatic oxidation or autoxidation of docosahexaenoic acid (DHA) produces 8 
hydroxy- docosahexaenoic acids (HDoHEs) and hydroperoxy- docosahexaenoic acids 9 
(HpDoHEs); moreover, it has been recently shown that DHA gives rise to a novel 10 
family of strong anti-inflammatory compounds termed neuroprostanes with dihydroxy 11 
(protectins, PD) and trihydroxy (series-D resolvins) structures [3][8]. (Figure S1 of 12 
Electronic Supplementary Material shows the similar formation cascades of ARA, EPA 13 
and DHA fatty acids). 14 
 15 
Oxygenated metabolites of PUFAs have an important role in a wide range of biological 16 
functions. They are part of membrane cells, activate gene transcription, and are also 17 
involved in many diseases and inflammatory processes [9][10]. Therefore, these lipid 18 
mediators have been investigated in biomarkers discovery and drug development 19 
studies [3]. Specific examples include the pro-inflammatory role of ARA eicosanoids 20 
and isoprostanes metabolites in many processes related to oxidative stress, such as 21 
hypercholesterolemia [11], liver cirrhosis [12], Crest syndrome [13], myocardial 22 
reperfusion [14] or type-2 diabetes [15][16]. On the other hand, many hydroxy derived 23 
compounds of EPA and DHA are involved in the regulation of vascular tone [17], 24 
arteriosclerosis [18] or Alzheimer [19], and are considered markers of lipid 25 
peroxidation. Finally, novel studies have related anti-inflammatory and cellular 26 
protective activities of RvE1, RvD1 and PD1 [20] to benefits in cardiovascular diseases, 27 
dry eyes or even Alzheimer [21][22]. 28 
 29 
The analytical determination of oxygenated  PUFA metabolites is a challenging task, 30 
mainly because of their low physiological levels and large number of isomers with very 31 
similar physicochemical properties [10]. Therefore, a sensitive and selective detection 32 
procedure following an effective separation step is essential to comprehensively study 33 
this class of lipids [23]. Methods used for the determination of these lipid mediators 34 
currently involve an extraction and/or pre-concentration step followed by the 35 
chromatographic separation and mass spectrometry determination. The most common 36 
Solid-phase extraction (SPE) sorbents are C18 conventional cartridges [16][24][25], and 37 
polymeric sorbents like Oasis-HLB [26][27][28] or Strata-X [29][30]. For many years, 38 
gas chromatography coupled to mass spectrometry (GC/MS) was the method of choice 39 
for eicosanoids analysis [15][17][31]. Nowadays, the widespread liquid 40 
chromatography/mass spectrometry (LC-MS) coupled with high-sensitivity electrospray 41 
ionization (ESI) has provided a new approach for quantification, minimizing sample 42 
preparation requirements and particularly avoiding derivatization reactions 43 
[3][24][25][32][33]. The triple quadrupole (QqQ) mass spectrometer working in the 44 
multiple reaction monitoring (MRM) mode [16][26][28][29][30], together with hybrid 45 
variants such as quadrupole ion trap (Q-Trap) [27][34] and quadrupole time-of-flight 46 
(Q-TOF) [35][36], have become the MS technology of choice for analysis of 47 
oxygenated PUFA metabolites. 48 
 49 
 3
The aim of this research was to develop an analytical methodology based on SPE and 1 
LC-MS, to allow the simultaneous detection and quantification of a wide range of lipid 2 
mediators in plasma. PUFA derivatives like prostaglandins, leukotrienes, tromboxanes, 3 
hydroxy and hydroperoxy acids, isoprostanes, resolvins and protectins derived from 4 
ARA, EPA and DHA and their fatty acid precursors were the target analytes. The 5 
proposed method innovatively attempts to analyze PUFA metabolites with a wide range 6 
of polarity (octanol-water partition coefficients ranged from 1.1 of PGD3 to 7.3 of 7 
DHA), concentration (up to 4 orders of magnitude), stability diversity (hydroperoxides 8 
are highly unstable), and applies polymeric  HLB cartridges for the extraction of 9 
hydroxy and hydroperoxy PUFA congeners. Two different mass spectrometers were 10 
tested in order to discuss and compare both acquisition modes in terms of false positive 11 
identifications: a QqQ acquiring in the MRM mode that is commonly applied to 12 
lipidomic approaches, and a Linear Ion Trap (LIT) acquiring in full scan product ion 13 
mode. Their analytical parameters for optimal sensitivity and selectivity were addressed. 14 
Applicability of the analytical platform was validated by analyzing plasma samples of 15 
genetically obese spontaneously hypertensive rats. 16 
 17 
2. Experimental 18 
2.1. Standards, solvents and sorbents 19 
Thromboxane B3 (TXB3, 9α-(±)11,15(S)-trihydroxy-thromba-5Z,13E,17Z-trien-1-oic 20 
acid), prostaglandin D3 (PGD3, 9α-15(S)-dihydroxy-11-oxo-prosta-5Z,13E,17Z-trien-1-21 
oic acid), prostaglandin E3 (PGE3, 11α-15(S)-dihydroxy-9-oxo-prosta-5Z,13E,17Z-22 
trien-1-oic acid), prostaglandin E2 (PGE2, 11α-15(S)-dihydroxy-9-oxo-prosta-5Z,13E-23 
dien-1-oic acid), resolvin D1 (RvD1, 7(S),8(R),17(S)-trihydroxy-24 
4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid), protectin D1 (PD1, 10(S),17(S)-25 
dihydroxy-4Z,7Z,11E,13Z,15E,19Z-docosahexaenoic acid), leukotriene B4 (LTB4, 26 
5(S),12(R)-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid), isoprostane F2α 27 
(8isoPGF2α, 9α,11α,15(S)-trihydroxy-8β-prosta-5Z,13E-dien-1-oic acid), isoprostane 28 
F3α (8isoPGF3α, 9α,11α,15(S)-trihydroxy-8β-prosta-5Z,13E,17Z-trien-1-oic acid), 29 
15HpEPE (15(S)-hydroperoxy-5Z,8Z,11Z,13E,17Z-eicosapentaenoic acid), 12HpEPE 30 
(12(S)-hydroperoxy-5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid), 17HpDoHE (17(S)-31 
hydroperoxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid), 15HEPE (±15-hydroxy-32 
5Z,8Z,11Z,13E,17Z-eicosapentaenoic acid), 12HEPE (±12-hydroxy-33 
5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid), 5HEPE (±5-hydroxy-6E,8Z,11Z,14Z,17Z-34 
eicosapentaenoic acid), 11HETE (±11-hydroxy-5Z,8Z,12E,14Z-eicosatetraenoic acid), 35 
12HETE-d8 (12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic-5,6,8,9,11,12,14,15-d8 36 
acid), 17HDoHE (±17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid), 37 
11HDoHE (±11-hydroxy-4Z,7Z,9E,13Z,16Z,19Z-docosahexaenoic acid), 4HDoHE 38 
(±4-hydroxy-5E,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid), eicosapentaenoic acid 39 
(EPA, 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid), docosahexaenoic acid (DHA, 40 
4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid) and arachidonic acid (ARA, 41 
5Z,8Z,11Z,14Z-eicosatetraenoic acid) were purchased from Cayman Chemicals (Ann 42 
Arbor, MI, USA). The suppliers stated purities higher than 96% for all standards. 43 
 44 
Stock standard solutions of all analytes were prepared in ethanol and stored at -80 ºC 45 
under nitrogen. Individual stocks (5 μg/mL) were used to optimize ESI ionization and 46 
MS/MS fragmentation conditions by flow injection analysis. 47 
 48 
For most species, calibration standard solutions were prepared in the range between 1 49 
and 500 ng/mL. Two additional calibration solutions (1000 and 1500 ng/mL) were 50 
 4
made for 12HEPE. A second series of calibration standards from 100 to 50000 ng/mL 1 
was prepared for parent PUFAs (EPA, ARA, DHA) due to their higher concentration in 2 
plasma samples. The internal standard (11HETE-d8) was included in all calibration 3 
solutions at a constant level of 500 ng/mL. Calibration lines were calculated by the 4 
least-squares linear regression method with the internal standard correction. 5 
 6 
Methanol, Optima LC-MS grade, was purchased from Fisher Scientific (New Jersey, 7 
USA); ultrapure water was obtained from a Milli-Q system (Millipore, Bedford, MA, 8 
USA); methyl formate was purchased from Sigma Aldrich (Poole, UK); n-hexane was 9 
provided by Merk (Darmstadt, Germany) and ethanol, formic acid and hydrochloric 10 
acid were from AnalR Normapur (Fontenai, France). SPE cartridges (C18-SepPak, 100 11 
mg, 1 mL and Oasis-HLB, 60 mg, 3 mL) were supplied by Waters (Milford, MA, 12 
USA). 13 
 14 
2.2. Samples and sample preparation 15 
Plasma samples were collected from female SHROB (genetically obese spontaneously 16 
hypertensive) rats, an animal model of metabolic syndrome. Animals were kept in an 17 
isolated room with a constantly regulated temperature (22±2 ºC) and humidity 18 
(50±10%) in a 12 h artificial light cycle, and fed ad libitum with water and a standard 19 
pelleted chow diet A04 from Harlan Ibérica (Barcelona, Spain), which contained on wet 20 
basis 60% carbohydrate, 16% protein and 3% fat. Rats were sacrificed by 21 
exsanguination, blood was collected in tubes with ethylenediaminetetraacetic acid 22 
(EDTA) to obtain plasma (as described below). All the procedures performed agreed 23 
with the national and institutional guidelines of the Animal Care and Use Committee at 24 
the CSIC. 25 
 26 
Blood was centrifuged at 850 g (4 ºC, 15 min) in the presence of EDTA to remove 27 
erythrocytes. Then, plasma was supplemented with 5 mM phenylmethylsulfonyl 28 
fluoride (PMSF, protease inhibitor) and erythrocyte free samples were immediately 29 
stored at -80 ºC until use. A pre-treatment step for small fluids was applied to plasma 30 
samples before the SPE [37]. The defrosting process was carried out slowly in darkness, 31 
to prevent possible analytes oxidation and degradation. Samples (90 µL) were diluted 32 
with cold methanol 30% (v/v) to a final volume of 1 mL, and spiked with the internal 33 
standard (IS) 11HETE-d8. Samples were incubated on ice for 10 min and then 34 
centrifuged at 5000 rpm for 10 min, at 4 ºC, to remove potential proteins that may cause 35 
interference. Supernatant and washes of the resultant pellet with 30% methanol were 36 
collected in amber glass vials and added to SPE cartridges. 37 
 38 
SPE extractions were carried out in a cold room at 4 ºC. Cartridges were conditioned 39 
with 5 mL methanol followed by 5 mL Milli-Q water. After sample loading, cartridges 40 
were sequentially washed with 5mL 15% methanol (v/v), 5 mL Milli-Q water and 2.5 41 
mL hexane. Then, the sorbent phase was dried under a stream of nitrogen for 30 min 42 
and analytes were eluted using 2 mL methyl formate. The extraction procedure was 43 
performed using a vacuum manifold; the vacuum was adjusted so that individual drops 44 
could be seen from each cartridge. Extracts were evaporated to dryness under a fine 45 
stream of nitrogen; the residue was dissolved in 30 µL ethanol and stored at -80 ºC prior 46 
to LC-MS/MS analysis. 47 
 48 
It is important to notice that during the sample spiking procedure, precursor fatty acids 49 
could be degradated rending hydroperoxy derivates. Also, impurities existing in the 50 
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commercial standards of EPA, ARA and DHA can become important since their 1 
addition level was huge in relation to the rest of compounds. To avoid these potential 2 
problems, three sets of spiked samples were prepared in order to separately evaluate the 3 
recoveries of precursor fatty acids, hydroperoxy and the rest of analytes. Addition levels 4 
used in these sets of spiked samples were 150 ng/mL for PUFAs metabolites, except for 5 
12HEPE (600 ng/mL). Their precursors were added to plasma at much higher levels: 6 
EPA (3 μg/mL), DHA (15 μg/mL) and ARA (45μg/mL), which are in the same order of 7 
concentration as existing in non-spiked (blank) samples. The added concentration of IS 8 
(12HETE-d8) was 500 ng/mL in all experiments. 9 
 10 
Different recovery experiments were performed according to the step procedure where 11 
the compounds were spiked: at the beginning of the process (Global recovery, SPE-LC-12 
ESI-MS/MS), after SPE (Matrix effect, ESI-MS/MS) or comparing initial spiked 13 
samples with additions done after SPE (SPE recovery). The repeatability of the 14 
methodology was expressed as percentage of relative standard deviation (%RSD). 15 
 16 
2.3. Apparatus 17 
Analyses were carried out on two LC-MS systems. One system consists of two ProStar 18 
210 high-pressure mixing pumps (Varian, Walnut Creek, CA, USA), a Metachem 19 
Technologies vacuum membrane degasser (Bath, UK), and an autosampler and 20 
thermostated column compartment ProStar 410 module (Varian). This LC is coupled 21 
with a triple quadrupole 320-MS equipped with an electrospray interface (Varian). 22 
Nitrogen, used as nebulising and drying gas, is provided by a nitrogen generator 23 
(Domnick Hunter, Durham, UK). Argon (99.999%) was used as collision gas. 24 
Instrument control and data acquisition were done by Varian MS Workstation software. 25 
 26 
The other LC system consists of an Agilent 1260 Series (Agilent, Palo Alto, CA) that 27 
includes a binary pump, a degasser system and a thermostated autosampler, coupled to a 28 
linear ion trap (LIT) mass spectrometer LTQ Velos Pro equipped with an electrospray 29 
interface (Thermo Fisher, Rockford, IL, USA). Nitrogen was used as nebulising and 30 
drying gas and helium was the collision gas. Instrument control and data acquisition 31 
were done with Xcalibur software. 32 
 33 
A Waters C18-Symmetry column, 150×2.1 mm, 3.5 μm (Milford, MA, USA) protected 34 
with a 4×2mm C18 guard cartridge provided by Phenomenex (Torrance, CA, USA) was 35 
used to perform LC separations in both systems. SPE clean-up and extraction steps were 36 
performed using a vacuum manifold system from Supelco (Bellefonte, PA, USA) 37 
coupled to a vacuum pump from Millipore (Bedford, MA, USA). Plasma samples were 38 
foremost centrifuged in an Avanti J25 refrigerated centrifuge (Beckman Coulter, USA). 39 
 40 
2.4. LC-MS/MS conditions 41 
A binary eluent system of water (A) and methanol (B), both with 0.02% (v/v) of formic 42 
acid, was used as mobile phase in the LC separation. The gradient was: 0-1 min (60% 43 
B), 2-12 min (80% B), 13-23 min (100% B), and 25-30 min (60% B). The flow rate was 44 
set to 0.2 mL/min, the column effluent was directly introduced in the ESI interface 45 
without splitting, and injection volume was set to 10 μL. The column was maintained at 46 
room temperature and extracts were kept at -20 ºC right up the injection moment. 47 
Retention times for target compounds are shown in Table 1. 48 
 49 
2.4.1. QqQ system 50 
 6
The ESI interface was operated in the negative mode with a needle potential of -4 kV, a 1 
source temperature of 50 °C, a desolvation temperature of 200 °C, a nebulising gas 2 
pressure of 55 psi (380 kPa) and a drying gas pressure of 20 psi (138 kPa). Argon 3 
pressure in the collision cell was kept at 2 mTorr for MS/MS measurements. The mass 4 
window of the first and last quadrupoles was adjusted to 2.0 and 1.5 amu, respectively. 5 
 6 
Selection of the most intense MS/MS transitions was done by direct infusion of 7 
individual standard solutions (5 μg/mL) at a flow rate of 20 μL/min. The intensity of the 8 
[M-H]- ion was optimized by varying the capillary voltage, and subsequently, the [M-9 
H]- ion was subjected to MS/MS fragmentation experiments and the most intense 10 
product ions were obtained by varying the collision energy (0 to 60 eV) with the aid of 11 
the automated routines included in the software package. For each analyte, the two most 12 
intense or selective transitions were selected (Table 1). 13 
 14 
2.4.2. LIT system 15 
Operating conditions of the ESI source were negative ion mode with a sheath gas flow 16 
rate of 40 units, spray voltage of 5.5 kV, capillary temperature of 300 ºC and S-lens 17 
radio-frequency level of 60%. Mass spectrometer was tuned optimizing voltages on the 18 
lenses and trap conditions whilst infusing standard solutions in the same way as QqQ 19 
system. The collision induced dissociation (CID) energy was optimized for each 20 
compound in order to maximize the intensity of their product ions. The identification of 21 
targeted compounds was helped with the full ion product spectra recorded in the range 22 
from 90 to 400 m/z units. To quantify the analytes, the most intense and selective 23 
transition was used. Individual MS/MS parameters for each compound are summarized 24 
in Table 1. 25 
 26 
3. Results and discussion 27 
3.1. Optimization of LC-ESI-MS/MS conditions 28 
Table 1 summarizes the optimal MS/MS transitions selected for the QqQ and LIT 29 
assays. These transitions were recorded in order to facilitate the individual identification 30 
of the compounds minimizing further false positive identifications in biological 31 
samples. Once transitions were set, compounds were chromatographically separated on 32 
a C18 column using a gradient of water/methanol solvents with 0.02% formic acid 33 
(v/v). Several compounds coeluted under the same chromatographic peak, but they 34 
could be individually quantified using specific transitions except for the particular case 35 
of the coeluting isomers PGE3 and PGD3 that also showed the same fragmentation 36 
pattern (Figure S2 of Electronic Supplementary Materialpresents their individual mass 37 
spectrum). MS3 fragmentations tested for both prostaglandins in the LIT spectrometer 38 
did not provide further qualitative information; therefore, they were quantified together. 39 
 40 
The LC separation cycle takes 30 min, including a 5 min column conditioning step 41 
before the next injection. Overall, this running time was comparable with other reported 42 
LC methods of eicosanoids analysis and provides the basis for a rapid assay [4][38]. 43 
Some of the selected product ions for QqQ were in agreement with the available 44 
literature values as the following: TXB3 367>169, 8iso-PGF2α 353>192, PGE2 351>271, 45 
5HEPE 317>115 or 17HDoHE 343>281. However, for these compounds, the found LIT 46 
transitions were different than those previously reported. Transitions associated to 47 
RvD1, LTB4, 12HEPE or 11HETE matched with literature values described for both 48 
equipment [3][24][28][29]. Figure 1 shows representative chromatograms of the 49 
analysis of these compounds. 50 
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 1 
3.2. Detection method validation 2 
Table 2 shows the values of linearity (from 1 to 500 ng/mL for oxidized derivates and 3 
100 to 50000 ng/mL for PUFAs), instrumental LODs and LOQs (defined for a signal to 4 
noise ratio of 3 and 10, respectively), and repeatability estimated by either of the two 5 
mass detectors. The standard calibration functions confirmed that both equipment 6 
achieved linear responses for all compounds, R2 ranged between 0.9860 and 0.9999. 7 
Acceptable precision was achieved by both instruments; RDSs % were lower than 12% 8 
except for hydroperoxy compounds at 5 ng/mL level. 9 
 10 
Finally, instrumental LODs and LOQs for the QqQ system were respectively estimated 11 
to be in the range of 0.003-7 and 0.01-23 ng/mL, and that is in agreement with those 12 
previously reported in literature [3][16][24][26][28][30][39]. LIT mass spectrometer 13 
achieved respectively LODs and LOQs between 0.002-3 and 0.006-10 ng/mL, values 14 
similar to those reported in a hybrid system consisting on a quadrupole-ion trap mass 15 
analyzer (QTrap) operating in MRM mode [27]. No previous reports were found using a 16 
linear ion trap spectrometer operating in full scan product ion mode. 17 
 18 
3.3. Optimization of solid-phase extraction (SPE) 19 
3.3.1 Breakthrough and elution solvent volume, washing conditions and extraction 20 
sorbent. 21 
In preliminary SPE experiments, aqueous samples (simulating plasma conditions) were 22 
used to optimize the SPE process trying two different cartridges, 60 mg Oasis-HLB and 23 
100 mg C18. Methyl formate and ethanol were tested as eluting solvents achieving the 24 
same performance; even though, methyl formate was selected due to its higher volatility 25 
that facilitates the later stage of concentration. Three consecutive 2 mL fractions of 26 
organic solvent were collected from SPE cartridges, previously spiked with 50 μL of a 27 
mixture solution of target compounds (200 ng/mL). Responses measured in the first 28 
fraction represented more than 98% of the total for all compounds. Thus, 2 mL of 29 
methyl formate were the optimal eluting conditions employed in further experiments. 30 
This extract was concentrated to dryness and finally re-constituted with 30 μL of 31 
ethanol. 32 
 33 
The breakthrough volume of both sorbents was investigated using up to 3 mL spiked 34 
aqueous samples passed through two cartridges connected in series (C18>C18 and 35 
HLB>HLB) and eluted separately. This sample volume, 3 mL, did not achieve the 36 
sorbent breakthrough volume due to none of the compounds were detected in the extract 37 
from the second cartridge, neither C18 nor HLB. 38 
 39 
Considering biological and complex samples, many authors have demonstrated the 40 
importance of a washing sample step during the SPE procedure to reduce sample 41 
complexity and to prevent matrix effects during LC-ESI-MS determination. Washing 42 
conditions were set to 5 mL of water followed by 5 mL of 15% methanol and 2.5 mL of 43 
hexane [16][24][26][30] after verifying that none of the compounds were lost in the 44 
washing fraction. 45 
 46 
Recoveries attained with Oasis-HLB and C18 cartridges were compared for 2 mL of 47 
spiked water samples at a final concentration of 150 ng/mL per compound. The 48 
comparative recovery results showed that HLB cartridges performed better than C18 49 
ones for precursor fatty acids and hydroxy compounds, for which HLB recoveries 50 
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ranged from 70 to 98% while those were reduced to 42 to 82% with the C18 sorbent 1 
(Figure 2). Eicosanoids, resolvins and protectins were eluted with similar recoveries (70 2 
to 105%) in both sorbents (Figure 2), and they are in agreement with other published 3 
results using HLB [24][25] and C18 [26][27]. Hydroperoxy compounds recoveries were 4 
higher using HLB sorbent than C18, but they still ranged from 50 to 70%, so that 5 
further optimization of the process was required. On the basis of results depicted in 6 
Figure 2, it was decided to select the HLB sorbent (never tested for hydroxy and 7 
hydroperoxy metabolites) to continue with optimization of the extraction process. 8 
 9 
3.3.2 Effect of sample pH, organic modifiers addition and temperature. 10 
When the SPE conditions described in the above section for aqueous solutions were 11 
applied to plasma samples, a decrease in the yield of SPE process was noticed for all 12 
compounds. Thus, additional variables were evaluated in order to better understand the 13 
behavior of the analytes during the sample preparation process and, obviously, to 14 
improve the yield of sample preparation. 15 
 16 
Some authors have suggested that acidification of plasma to pH 3 before extraction, 17 
improves the affinity of fatty acids and their derivatives by reversed-phase sorbents, and 18 
thus the efficiency of SPE extraction [3][40][41]. However, we found similar 19 
efficiencies for acidified (pH 3) and non-acidified plasma samples (data not shown); 20 
thus, the pH of plasma was not modified. 21 
 22 
The three fatty acids involved in this study (ARA, EPA and DHA) and their hydroxy 23 
and hydroperoxy derivatives are relatively lipophilic compounds; thus, these 24 
compounds are more prone to be lost by lipophilic interactions with the pellet formed 25 
after sample centrifugation, and that could partially explain their low recoveries 26 
obtained. In order to verify this hypothesis, a series of experiments were performed by 27 
diluting spiked plasma samples (90 μL) with aqueous solutions (1 mL) containing 28 
different percentages of methanol from 0 to 50%. After centrifugation, the supernatants 29 
were submitted to the SPE procedure and absolute recoveries calculated (Figure 3). In 30 
general, recoveries obtained for most compounds increased with the percentage of 31 
added methanol from 0 to 30% (quantitative recoveries were achieved with 30% of 32 
methanol). The exception to this trend corresponded to the free fatty acids (ARA, EPA 33 
and DHA). Quantitative recoveries for these species were only achieved using a 50% of 34 
methanol, which is in agreement with their high octanol-water partition coefficients 35 
(Kow (ARA, 25 ºC)=6.99, Kow (EPA, 25 ºC)=6.50, Kow (DHA, 25 ºC)=7.26). However, methanol 36 
proportions above 30%, reduced the recovery for the more water-soluble species 37 
(eicosanoids, resolvins and protectins) due to breakthrough problems in the cartridge. 38 
Thus, 30% of methanol was the optimized organic modifier used to favor the extraction 39 
of PUFAs minor metabolites in plasma. In the specific case of hydroperoxy compounds, 40 
the best recoveries were also obtained with 30% of methanol. 41 
 42 
The influence of the temperature during the extraction process was then checked 43 
comparing spiked plasma processed at room temperature and 4 ºC. Our results 44 
demonstrated that temperature had a critical impact on hydroperoxy compounds; whilst 45 
it did not affect the rest of studied analytes (Figure 4). Hydroperoxy recoveries were 46 
around 50% at room temperature, whereas such recoveries increased to 90-100% at 4 47 
ºC. Therefore, this is a critical parameter to be controlled in the global extraction 48 
process of lipid mediators. 49 
 50 
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To summarize, the optimal extraction conditions were set as follows: 90 μL of internal 1 
standard-spiked plasma were diluted with 1 mL 30% methanol. After centrifugation, the 2 
supernatant was recovered and loaded into the barrel of an Oasis-HLB 60mg SPE 3 
cartridge. The entire process was performed at 4 ºC. A scheme of optimized SPE 4 
method is provided as Electronic Supplementary Material in Figure S3. 5 
 6 
3.4. Repeatability, SPE-LC-MS recoveries and matrix effects 7 
Table 3 summarizes the repeatability of the entire optimized method, the overall 8 
recoveries for the SPE and SPE-LC-MS procedures, and the matrix effects for spiked 9 
plasma samples to a final concentration of 150 ng/mL per compound except for 10 
12HEPE (600 ng/mL), EPA (3μg/mL), DHA (15μg/mL) and ARA (45μg/mL), using 60 11 
mg Oasis-HLB cartridges. 12 
 13 
Good and similar repeatabilities were obtained for the compounds using the two 14 
analyzers, with the exception of hydroperoxy analytes. Repeatabilities were ranged 15 
between RSD values of 1-15% (13-26% for hydroperoxy) by SPE-LC-ESI-QqQ and 3-16 
13% (11-25% for hydroperoxy) by SPE-LC-ESI-LIT system. Thus, the precision of the 17 
method is controlled by the sample preparation step rather than by the characteristics of 18 
the mass analyzer. 19 
 20 
Global recoveries for LIT ranged from 80 to 112%, and were generally higher than QqQ 21 
global recoveries. In particular, the QqQ system provided global recoveries as low as a 22 
27-38% for the three hydropexides (15HpEPE, 12HpEPE and 17HpDoHE) and the 23 
hydroxyl 4HDoHE. Global recoveries for RvD1 and PUFA precursors (ARA, EPA and 24 
DHA) were also significantly lower, 50-71%, with the QqQ configuration. SPE 25 
recoveries were around 100% in both equipments with the exception of RvD1 (67-75%). 26 
Thus, according to the results compiled in Table 3, the main parameter that affected the 27 
global recovery of analytes was the matrix effect. 28 
 29 
It is known that the sensitivity and accuracy of the mass spectrometry determinations 30 
can be influenced by the coelution of matrix components with ability to reduce or 31 
enhance the intensity of [M-H]- precursor ions. Matrix effects observed for the QqQ 32 
were higher than for the LIT. Seven compounds, i.e. the three hydroperoxides, 4HDoHE 33 
and the three PUFA precursors, showed suppression of 28-71% of their signal with the 34 
QqQ, whilst with the LIT system only the precursor DHA and 11HDoHE exhibit matrix 35 
effect by losing their signal up to 29-20%, respectively. There might be multiple reasons 36 
for the different matrix effects observed on the two systems. Ion suppression mainly 37 
occurs in the early stages of the ionization process; therefore, the difference in matrix 38 
effect contribution may be in part due to the particular design of the ESI source of each 39 
system [42]. 40 
 41 
3.5. Application to plasma analysis 42 
The optimized SPE-LC-MS/MS method was applied to plasma samples of genetically 43 
obese spontaneously hypertensive rats. Samples were analyzed by both instrumental 44 
systems and results were compared. As it has been assessed above, both equipments 45 
achieved similar quantitative performance in the analysis of standard compounds; 46 
however, the MRM acquisition mode (QqQ) gave several false identifications when it 47 
was applied to rat plasma samples. The QqQ system was not able to distinguish targeted 48 
compounds from other coeluting isomers with similar MRM transitions. It should be 49 
noted that oxygenated PUFA metabolites comprise an elevated number of isomeric and 50 
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isobaric species that may coelute [23]. In contrast, the full ion product mode (LIT) 1 
provided full MS/MS spectra which help to minimize the number of false positive 2 
identifications. As example, when plasma samples were analyzed by MRM mode, 3 
11HDoHE was tentatively identified based on 343>121 m/z quantification and 343>149 4 
m/z identification transitions; and on the retention time 18.33 and 18.25 min for the 5 
sample and standard solution (Figure 5a,b). However, the LIT MS/MS spectra obtained 6 
for the same peak revealed that its fragmentation pattern is different from the 11HDoHE 7 
standard (Figure 5c,d). This peak was probably a different coeluting hydroxy derivate of 8 
DHA, based on the typical fragments attributed to neutral loses of water (343>325 and 9 
299>281 m/z) and CO2 (343>299) that were detected in both CID spectra. Different 10 
fragment ions from C-C cleavages were found (343>233, 255, 161 in the sample and 11 
343>194, 165, 149 in the standard). There are at least other 14 bioactive lipids with the 12 
same exact mass than 11HDoHE (MW: 344.235) [23], that in the case of coelution may 13 
explain the observed false positive identification in plasma analysis. In a similar way, 14 
the full ion product mode confirmed the false positive identification of 15HEPE, 15 
5HEPE and 4HDoHE using the MRM mode. 16 
 17 
Quantitative results obtained with the LIT instrument are presented in Table 4. Eight of 18 
twenty-three searched compounds were identified. ARA was the metabolite found at 19 
highest level (59446 ng/mL) and TXB3 was that present at the lowest concentration (3 20 
ng/mL). Due to the concentration level of 17HpDoHE was higher than the maximum 21 
level of calibration, it was necessary to dilute the samples. 22 
 23 
4. Conclusions 24 
The present work describes the development of a robust and sensitive targeted analysis 25 
platform for the simultaneous quantification in blood plasma of a larger number of 26 
eicosanoids/docosanoids (tromboxanes, prostaglandins, resolvins, protectins, 27 
leukotrienes, isoprostanes, hydroxy and hydroperoxy) which are quantified jointly to 28 
their PUFA precursors (ARA, EPA and DHA). The developed method overcame issues 29 
associated to the wide range of polarity (octanol-water partition coefficients ranged 30 
from 1.1 of PGD3 to 7.3 of DHA), concentration (up to 4 orders of magnitude) and 31 
stability diversity (hydroperoxides are highly unstable) of these metabolites. Two mass 32 
detectors were tested: the most common used QqQ instrument operating in MRM and 33 
LIT spectrometer acquiring in full ion product scan mode. Although the QqQ assays 34 
were highly sensitive and selective and chromatographic separation was optimized, the 35 
full ion product scan acquisition on the LIT analyzer was more appropriated to 36 
minimize false positive identifications for these metabolites. The optimized 37 
methodology is simple, sensitive, high-throughput and lends itself to lipidomic 38 
applications. The method can be used to biological applications targeted for biomarker 39 
discovery or other therapeutic and pharmacological approaches. It can be combined 40 
with information on metabolic, proteomic and genomic profiles providing global 41 
evidence for evaluating the role of lipids at cellular, tissue and system level. 42 
 43 
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7. Captions 1 
 2 
Figure captions 3 
 4 
Figure 1: Representative LC-MS/MS chromatograms of the 23 lipid mediators (75 5 
ng/mL, per compound) provided by the LIT instrument. 6 
 7 
Figure 2: Comparative SPE recovery results between 60 mg HLB and 100 mg C18 8 
cartridges, of 2 mL spiked water samples with a final concentration of 150 ng/mL per 9 
compound. The same extraction conditions were applied, at room temperature and 10 
neutral pH, n=3 replicates. 11 
 12 
Figure 3: Comparative recovery results for the extraction with 60 mg HLB cartridges of 13 
spiked plasma samples (final concentration of 150 ng/mL per compound except for 14 
12HEPE (600 ng/mL), EPA (3 μg/mL), DHA (15 μg/mL) and ARA (45 μg/mL)) 15 
supplemented with different percentages of methanol, 0 to 50%, n=3 replicates. 16 
 17 
Figure 4: Comparative recovery results for the extraction with 60 mg HLB cartridges of 18 
spiked plasma samples (final concentration of 150 ng/mL to every compound except 19 
12HEPE (600 ng/mL), EPA (3 μg/mL), DHA (15 μg/mL) and ARA (45 μg/mL)) doing 20 
the whole process at room temperature and 4 ºC, n=3 replicates. 21 
 22 
Figure 5: Identification of 11HDoHE using QqQ (a, b) and LIT (c, d) mass 23 
spectrometers: a) chromatogram obtained in the MRM mode (QqQ) at the transition of 24 
343>121 m/z in plasma sample; b) chromatogram obtained in the MRM mode (QqQ) at 25 
the transition of 343>121 m/z in standard solution of 11HDoHE; c) corresponding 26 
MS/MS spectrum of the identified peak in plasma sample with the LIT; d) 27 
corresponding MS/MS spectrum of 11HDoHE standard solution with the LIT. Spectra c 28 
and d demonstrate the false positive identification of 11HDoHE in plasma by QqQ 29 
analysis. 30 
31 
 16
 1 
Table captions 2 
Table 1: Retention times, collision energies and MS/MS transitions for QqQ and LIT 3 
spectrometers. 4 
 5 
Table 2: Linearity (1 to 500 ng/mL for oxidized derivates and 100 to 50000 ng/mL for 6 
PUFAs), limit of detection (LOD), limit of quantification (LOQ) and repeatability of 7 
LC-ESI/MS/MS assay at three concentration levels (5, 100 and 500 ng/mL) for target 8 
compounds for the QqQ and LIT mass spectrometers. *The Repeatability of EPA, ARA 9 
and DHA was determined at three different concentration levels: 100, 5000 and 50000 10 
ng/mL (n=5). 11 
 12 
Table 3: Repeatability (RSD) of the global process and recovery results including: 13 
Global Recovery (SPE-LC-ESI/MS/MS), SPE Recovery and Matrix Effect (LC-14 
ESI/MS/MS); for spiked plasma samples (n=3) to a final concentration of 150 ng/mL 15 
per compound except for 12HEPE (600 ng/mL), EPA (3 μg/mL), DHA (15 μg/mL) and 16 
ARA (45 μg/mL). Comparison between QqQ and LIT spectrometers. 17 
 18 
Table 4: Average concentration and calculated RSD of studied lipid compounds in ten 19 
female rat plasma samples by SPE-LC-LIT. A dilution was needed to calculate 20 
17HpDoHE concentration due to his level in samples was higher than the maximum 21 
level of calibration. 22 
 23 
Electronic Supplementary Material 24 
Figure S1: Cascade of formation to ARA, EPA and DHA oxidized derived compounds 25 
from COX, LOX, CYP450 enzyme activities and autoxidation. 26 
 27 
Figure S2: Individual mass spectrum and a possible explanation of the fragmentation 28 
patterns for PDG3 and PGE3 isomers. 29 
 30 
Figure S3: Optimized SPE methodology for plasma samples containing lipid mediator 31 
derivatives. 32 
 17 
8. Tables 
Table 1 
Compound Retention Time (min) QqQ LIT 
Collision energy (eV) Capillary voltage (eV) MRM quantificationq and identificationi transitions (m/z) Collision energy (eV) Quantification transition (m/z) 
8iso-PGF3α 6.79 18 
14.5 
-68 351>307 q 
351>333 i 
30 351>253 
TXB3 6.97 16.0 
13.5 
-52 367>169 q 
367>195 i 
19 367>195 
PGD3/PGE3 7.67 12.5 
10 
-40 349>269 q 
349>313 i 
19 349>313 
8iso-PGF2α 8.28 27.0 
24.5 
-44 353>192 q 
353>171 i 
28 353>299 
PGE2 9.09 15.5 
10.5 
-64 351>271 q 
351>315 i 
20 351>315 
RvD1 9.80 14.0 
18.0 
-56 375>141 q 
375>215 i 
25 375>141 
PD1 12.89 16.0 
19.0 
-64 359>153 q 
359>136 i 
30 359>153 
LTB4 13.79 15.0 
12.5 
-80 335>195 q 
335>317 i 
27 335>195 
15HpEPE 17.36 9.5 
5.0 
-30 333>111 q 
333>315 i 
20 333>315 
12HpEPE 17.80 5.5 
9.0 
-32 333>271 q 
333>151 i 
25 333>315 
15HEPE 17.92 11.0 
11.5 
-56 317>219 q 
317>255 i 
27 317>219 
12HEPE 18.72 12.5 
12.0 
-56 317>179 q 
317>208 i 
27 317>179 
5HEPE 20.47 12.5 
10.5 
-56 317>115 q 
317>255 i 
25 317>255 
17HpDoHE 21.90 9.5 
5.5 
-32 359>111 q 
359>297 i 
26 359>341 
17HDoHE 21.94 11.5 
12.5 
-64 343>281 q 
343>201 i 
27 343>245 
11HETE 22.09 15.0 
12.5 
-80 319>167 q 
319>301 i 
30 319>167 
12HETEd8 22.66 13.5 
12.0 
-68 325>182 q 
325>307 i 
30 325>307 
11HDoHE 23.20 14.0 
12.5 
-60 343>121 q 
343>149 i 
27 343>149 
4HDoHE 23.64 13.5 
10.5 
-64 343>101 q 
343>281 i 
27 343>281 
EPA 24.43 10.0 
12.5 
-64 301>257 q 
301>203 i 
27 301>257 
DHA 24.93 9.5 
11.5 
-38 327>283 q 
327>229 i 
30 327>283 
ARA 25.10 13.5 
12.0 
-76 303>205 q 
303>259 i 
30 303>259 
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Table 2 
Compound R2 LOD(ng/mL) LOQ(ng/mL) Repeatability (RSD % n=5) 
QqQ LIT QqQ LIT QqQ LIT QqQ LIT 
5ng/mL 100ng/mL 500ng/mL 5ng/mL 100ng/mL 500ng/mL 
12HpEPE 0.9868 0.9991 2 3 6 10 22 4 5 3 3 2 
15HpEPE 0.9868 0.9991 0.4 0.6 1.5 2 16 4 2 3 3 2 
17HpDoHE 0.9879 0.9903 1 1 3.5 4 11 7 1 5 3 7 
11HDoHE 0.9965 0.9957 0.9 0.1 3 0.3 7 4 4 3 1 2 
11HETE 0.9997 0.9931 0.1 0.02 0.4 0.07 8 2 1 4 9 5 
12HEPE 0.9974 0.9939 0.7 0.08 2 0.3 7 6 2 4 1 1 
12HETEd8   0.003 0.002 0.01 0.006 3 3 4 5 6 4 
15HEPE 0.9997 0.9968 0.5 0.07 1.5 0.2 10 3 2 4 1 1 
17HDoHE 0.9999 0.9947 0.5 0.2 2 0.7 12 3 6 6 1 1 
4HDoHE 0.9921 0.9922 1.5 0.3 5 1 5 1 2 7 5 4 
5HEPE 0.9960 0.9938 0.5 0.1 2 0.3 4 3 6 4 1 1 
LTB4 0.9994 0.9954 0.3 0.03 1 0.1 6 1 1 3 2 1 
PD1 0.9997 0.9971 0.3 0.02 1 0.1 6 2 0.05 5 1 2 
PGD3/PGE3 0.9992 0.9985 0.2 0.1 1 0.3 2 1 3 1 1 2 
PGE2 0.9993 0.9925 0.1 0.05 0.4 0.2 6 1 1 2 1 1 
RvD1 0.9995 0.9958 0.1 0.02 0.4 0.07 6 1 2 1 1 2 
TXB3 0.9970 0.9971 0.4 0.1 1 0.5 5 2 1 4 1 1 
PGF2α 0.9992 0.9936 1 0.06 3 0.2 4 4 3 8 3 2 
PGF3α 0.9997 0.9959 7 0.4 23 1.5 5 3 2 2 1 1 
ARA 0.9997 0.9934 0.1 0.04 0.3 0.1 *6 *3 *1 *3 *5 *9 
EPA 0.9978 0.9959 0.1 0.01 0.2 0.04 *6 *3 *2 *3 *4 *7 
DHA 0.9876 0.9860 0.1 0.01 0.2 0.04 *2 *2 *3 *3 *5 *8 
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Table 3 1 
Compound %RSD (n=3) %Global Recovery %SPE Recovery Matrix Effect 
QqQ LIT QqQ LIT QqQ LIT QqQ LIT 
12HpEPE 13 11 27 88 91 99 29 88 
15HpEPE 19 22 37 88 106 99 35 88 
17HpDoHE 26 25 38 97 99 96 39 101 
11 HDoHE 5 5 97 94 100 118 97 80 
11 HETE 4 8 94 99 101 88 93 113 
12 HEPE 4 9 82 87 97 83 85 105 
15 HEPE 6 10 100 112 100 103 100 109 
17 HDoHE 6 6 111 109 125 123 89 88 
4 HDoHE 5 13 37 97 92 116 41 83 
5 HEPE 4 7 83 92 100 105 83 88 
LTB4 7 11 97 92 101 94 96 98 
PD1 5 11 98 86 97 98 100 88 
PGD3/PGE3 15 10 80 94 98 94 81 100 
PGE2 5 8 112 95 96 99 116 95 
RvD1 6 12 61 85 67 75 90 89 
TXB3 4 12 81 112 95 84 85 104 
8iso-PGF2α 13 8 91 86 92 85 99 102 
8iso-PGF3α 12 11 86 80 95 82 91 97 
ARA 3 4 71 100 99 111 72 90 
EPA 1 6 50 98 101 106 49 93 
DHA 6 3 60 88 116 123 51 71 
2 
 20
Table 4 1 
 2 
Compound Average sample 
concentration (ng/mL) 
(n=10) 
17HpDoHE 2183 ± 240 
11 HETE 3 ± 0.5 
12 HEPE 249 ± 69 
PGE2 10 ± 1 
TXB3 3 ± 0.4 
ARA 59446 ± 10105 
EPA 8370 ± 1255 
DHA 48632 ± 7781 
 21
 
9. Figures 
 
Figure 1 
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10. Electronic Supplementary material 
Figure S1 
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Figure S2 1 
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Figure S3 1 
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